July 15, 2019 – A paper about the University of Sydney and NSW Health clinical trial provides the first strong evidence that so-called cannabinoid agonist medication — which targets receptors in the brain — could reduce the rate of relapse. The paper published today in the American Medical Association’s JAMA Internal Medicine. Lead author Conjoint Professor Nick Lintzeris — of the University of Sydney’s Faculty of Medicine and Health and Director of Drug & Alcohol Services, South East Sydney Local Health District — said the study should give hope to people with dependency on cannabis, which is a leading cause of drug treatment episodes in Australia.*
“We’ve never had the evidence before that medication can be effective in treating cannabis dependency — this is the first big study to show this is a safe and effective approach,” Professor Lintzeris said. “The principles are very similar to nicotine replacement; you are providing patients with a medicine which is safer than the drug they’re already using, and linking this with medical and counselling support to help people address their illicit cannabis use.
VIDEO – AT THE GATES OF SALVATION – Nov. 18, 2024 - “He checked into…
TIME WILL TELL – Nov. 11, 2024 - President-elect Donald Trump is expected to come…
POT IS SO OBSOLETE – Nov. 15, 2024 - Cannabis is a “genotoxic” substance because…
NPR AUDIO – STICK WITH THE WINNERS! – Nov. 14, 2024 - “I don’t shoot…
NEW BOOK! READING MATTERS – Nov. 15, 2024 - “This is a pointed and urgent…
DON’T MISS THESE – 2023 - 1. “Barfly” (1987) Directed by Barbet Schroeder and based…